
Founded in 2012 and headquartered in Geneva, Switzerland, ObsEva SA (formerly Nasdaq: OBSV) was a biopharmaceutical company focused on developing and commercializing novel therapies for conditions in women's reproductive health and pregnancy. The company's pipeline included linzagolix (GnRH receptor antagonist for uterine fibroids and endometriosis) and ebopiprant (for preterm labor). ObsEva completed an IPO in 2018. Due to financial difficulties, the company undertook a strategic reorganization in 2023 and ultimately wound down operations and laid off all employees in February 2024.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account